Eli Lilly and Company $LLY Shares Bought by First Citizens Bank & Trust Co.

Key Points

• First Citizens Bank & Trust Co. increased its Eli Lilly stake by 22.3% in the third quarter, adding 7,019 shares to own 38,512 shares valued at approximately $44.6 million. Institutional investors collectively own 82.53% of LLY.
• Eli Lilly reported quarterly EPS of $8.38, beating estimates of $6.40, while revenue reached $22.97 billion, up 47.7% year over year and above expectations.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $1,313.43, though insiders sold 13,500 shares worth nearly $16 million over the past three months and the stock’s premium valuation leaves it exposed to disappointment.

First Citizens Bank & Trust Co. increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 22.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,512 shares of the company's stock after buying an additional 7,019 shares during the period. Eli Lilly and Company comprises approximately 0.6% of First Citizens Bank & Trust Co.'s investment portfolio, making the stock its 28th biggest holding. First Citizens Bank & Trust Co.'s holdings in Eli Lilly and Company were worth $44,561,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. State Street Corp lifted its stake in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock valued at $8,647,153,000 after purchasing an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC boosted its position in Eli Lilly and Company by 7.9% during the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock valued at $6,550,587,000 after purchasing an additional 400,538 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity

In related news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Down 1.3%

LLY stock opened at $1,167.01 on Wednesday. The stock has a market capitalization of $1.10 trillion, a PE ratio of 39.16, a price-to-earnings-growth ratio of 1.52 and a beta of 0.46. Eli Lilly and Company has a 52 week low of $783.85 and a 52 week high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a 50 day moving average of $1,176.60 and a 200 day moving average of $1,102.08.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm's revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 34.79 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on LLY. Guggenheim boosted their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a report on Friday, September 18th. BMO Capital Markets reissued an "outperform" rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 23rd. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an "overweight" rating in a research report on Monday, September 28th. Finally, Bank of America raised their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $1,313.43.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts raised earnings estimates. Erste Group increased its FY2026 EPS forecast to $36.55 from $36.45 and its FY2027 estimate to $47.30 from $47.18, both above current consensus expectations. Erste Group raises Eli Lilly earnings estimates
• Positive Sentiment: Retatrutide remains the key long-term catalyst. Ahead of Lilly’s October 29 earnings report, investors are focused on whether the experimental triple-action obesity drug could become a growth driver larger than Zepbound. Lilly’s expected 2026 revenue of up to $87 billion and strong weight-loss-drug demand support the bullish case. Why the Retatrutide story matters
• Positive Sentiment: New oncology collaboration expands the pipeline. Prelude Therapeutics will test its experimental KAT6A degrader PRT13722 with Lilly’s Verzenio and Inluriyo in a Phase 1 breast-cancer trial, with enrollment expected in the fourth quarter of 2026. The program is early-stage but could create additional value if clinical results validate the combination. Prelude and Lilly clinical trial collaboration
• Neutral Sentiment: Upcoming earnings are a near-term focus. Investors will look for updates on diabetes and obesity-drug sales, full-year guidance, and retatrutide’s development timeline. Expectations for a potential revenue-outlook increase are supportive, but the results could also heighten volatility given Lilly’s elevated valuation. Lilly may raise revenue outlook
• Negative Sentiment: Clinical data contained a drawback. A combination regimen produced more weight loss than Zepbound alone, but discontinuation rates were substantially higher, raising questions about tolerability and commercial adoption of next-generation obesity treatments. Obesity-drug combination results
• Negative Sentiment: Valuation leaves less room for disappointment. Commentary highlights that LLY trades at a premium multiple near its highs, making the stock vulnerable to profit-taking or weaker-than-expected pipeline updates despite exceptional growth. Eli Lilly valuation review

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.